Gavis Pharmaceuticals
- All
- News
-
Lupin Arm Gets US Regulator's Tentative Nod For Anti-Bacterial Drug
Drug firm Lupin on Thursday said US-based subsidiary Gavis Pharmaceuticals has received tentative approval from the US Food and Drug Administration (FDA) an anti-bacterial drug in the American market.
-
Lupin Arm Gets US Regulator's Nod To Market Bacterial Infection Drug
Drug major Lupin on Wednesday said its subsidiary Gavis Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) to market generic Linezolid tablets used for treating bacterial infection in the American market.
-
Lupin Gets USFDA Nod For Generic Potassium Deficiency Drug
Drug firm Lupin today said its subsidiary Gavis Pharmaceuticals has received final approval from the US health regulator to market potassium chloride extended release capsules, used for treating potassium deficiency in the bloodstream, in the American market.
-
Lupin Looks To Launch 25 Products In US This Fiscal Year
Drug major Lupin expects to launch nearly 25 products in the US market in 2016-17 that the company expects to be the key driver for its revenue growth going forward.
-
Lupin Gets USFDA Nod For Potassium Deficiency Treatment Drug
Pharma major Lupin's US arm Gavis Pharmaceuticals LLC has received final approval from the USFDA for its generic version of Upsher-Smith Labs' Klor-Con tablets used for treating potassium deficiency in blood.
-
Lupin Gets USFDA Nod For Fungal Infection Drug
Lupin has received final approval from the US health regulator to market generic Voriconazole tablets as well as oral suspension for treatment of fungal infections in the American market.
-
Lupin Gets US Drug Regulator's Final Nod For Fungal Treatment Drug
According to IMS MAT March 2016 sales data, Vfend tablets, 50 mg and 200 mg, had sales of $92.8 million while Vfend Oral Suspension, 40 mg/mL, had US sales of $15.9 million.
-
Lupin Completes Acquisition of GAVIS Pharma
Drug major Lupin on Wednesday said it has completed the acquisition of privately-held, US-based GAVIS Pharmaceuticals LLC and Novel Laboratories (GAVIS).
-
Lupin, Gavis to Sell 2 Drugs for Deal Approval
Homegrown drug major Lupin and Gavis Pharmaceuticals LLC, which the Indian firm announced to acquire in an $850-million deal last year, have agreed to divest two generic drugs as part of the US Federal Trade Commission's (FTC) requirement to complete the transaction.
-
Lupin Looks to Revive US Growth With $880-Million GAVIS Deal
Lupin Ltd, India's third-largest drug maker by sales, is buying US peer GAVIS Pharmaceuticals LLC for $880 million (Rs 5,588 crore at $1 = Rs 63.5) in its largest ever acquisition, seeking to revive its flagging growth in the United States, its largest market.
-
Lupin Arm Gets US Regulator's Tentative Nod For Anti-Bacterial Drug
Drug firm Lupin on Thursday said US-based subsidiary Gavis Pharmaceuticals has received tentative approval from the US Food and Drug Administration (FDA) an anti-bacterial drug in the American market.
-
Lupin Arm Gets US Regulator's Nod To Market Bacterial Infection Drug
Drug major Lupin on Wednesday said its subsidiary Gavis Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) to market generic Linezolid tablets used for treating bacterial infection in the American market.
-
Lupin Gets USFDA Nod For Generic Potassium Deficiency Drug
Drug firm Lupin today said its subsidiary Gavis Pharmaceuticals has received final approval from the US health regulator to market potassium chloride extended release capsules, used for treating potassium deficiency in the bloodstream, in the American market.
-
Lupin Looks To Launch 25 Products In US This Fiscal Year
Drug major Lupin expects to launch nearly 25 products in the US market in 2016-17 that the company expects to be the key driver for its revenue growth going forward.
-
Lupin Gets USFDA Nod For Potassium Deficiency Treatment Drug
Pharma major Lupin's US arm Gavis Pharmaceuticals LLC has received final approval from the USFDA for its generic version of Upsher-Smith Labs' Klor-Con tablets used for treating potassium deficiency in blood.
-
Lupin Gets USFDA Nod For Fungal Infection Drug
Lupin has received final approval from the US health regulator to market generic Voriconazole tablets as well as oral suspension for treatment of fungal infections in the American market.
-
Lupin Gets US Drug Regulator's Final Nod For Fungal Treatment Drug
According to IMS MAT March 2016 sales data, Vfend tablets, 50 mg and 200 mg, had sales of $92.8 million while Vfend Oral Suspension, 40 mg/mL, had US sales of $15.9 million.
-
Lupin Completes Acquisition of GAVIS Pharma
Drug major Lupin on Wednesday said it has completed the acquisition of privately-held, US-based GAVIS Pharmaceuticals LLC and Novel Laboratories (GAVIS).
-
Lupin, Gavis to Sell 2 Drugs for Deal Approval
Homegrown drug major Lupin and Gavis Pharmaceuticals LLC, which the Indian firm announced to acquire in an $850-million deal last year, have agreed to divest two generic drugs as part of the US Federal Trade Commission's (FTC) requirement to complete the transaction.
-
Lupin Looks to Revive US Growth With $880-Million GAVIS Deal
Lupin Ltd, India's third-largest drug maker by sales, is buying US peer GAVIS Pharmaceuticals LLC for $880 million (Rs 5,588 crore at $1 = Rs 63.5) in its largest ever acquisition, seeking to revive its flagging growth in the United States, its largest market.
